Zusammenfassung
Ösophaguskarzinome wurden bislang hauptsächlich chirurgisch in Kombination mit verschiedenen anderen Modalitäten wie etwa Strahlentherapie, Chemotherapie, Immuntherapie und Hyperthermie behandelt [1]. Die arterielle Infusionschemotherapie wurde bei Ösophaguskarzinomen aufgrund der anatomischen Komplexität nicht so weitreichend erforscht wie für die Behandlung anderer Krebsarten.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Taguchi T, Nakamura H, editors. Arterial infusion chemotherapy. Tokyo, Japan: Japanese Journal of Cancer and Chemother Publishers Inc; 1994. ISBN 0385–0684.
Ishida K, Murakami K. Protocol of therapy for esophageal cancer. Rinsho Geka (JPN). 1987;42:741–9.
Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol. 2008;13(6):474–8. ISSN 1341–9625.
Nygaard K, Hagen S, Hansen HS, et al. Preoperative radiotherapy prolongs survival in operable esophageal carcinoma; a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992; 16(6): 1104–9. discussion 1110.
Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.
Visser BC, Venook AP, Patti MG. Adjuvant and neoadjuvant therapy for esophageal cancer; a critical reappraisal. Surg Oncol. 2003;12:1–7.
Malthaner RA, Wong RK, Rumble RB, et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer; a systemic review and meta-analysis. BMC Med. 2004;2:35.
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus; a randomized controlled phage III trial. Lancet Oncol. 2005;6(9):659–68.
Gebski V, Burmeister B, Smithers BM, et al. Chemoradiotherapy or chemotherapy in oesophageal carcinoma; a meta-analysis. Lancet Oncol. 2007;8:226–34.
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26: 1086–92.
Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophageal gastric cancer. N Engl J Med. 2008;358:36–46.
Igaki H, Kato H, Ando N, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol. 2008; 26(suppl): 4510.
Luu TD, Gaur P, Force SD, et al. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Ann Thorac Surg. 2008;85(4): 1217–23.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Taguchi, T. (2013). Ösophaguskarzinom. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-35014-6_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35013-9
Online ISBN: 978-3-642-35014-6
eBook Packages: Medicine (German Language)